ClinicalTrials.gg
CompletedNCT00190983Updated Nov 20, 2009Results posted

A Trial for Patients With Advanced/Recurrent Cervical Cancer

A Phase 2 interventional study of Pemetrexed in Cervical Intraepithelial Neoplasia, Uterine Neoplasms and Genital Neoplasms, Female, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2009-11-20.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 109 studies in Uterine Cervical Dysplasia with a site in United States — 10 open to participants now, 14 under way, none of them phase 3. Uterine Cervical Dysplasia · United States.

Enrollment
60th of 86
29 · median 80
Started
2005
with 6 others
Phase 2
25 of 109
2 open now
Registered
17th of 109
by date

Among the 109 studies in Uterine Cervical Dysplasia with a site in United States, this one is the 60th largest by enrollment of the 86 interventional ones that give a count, is one of 7 that started in 2005, is one of 25 in phase 2, and was the 17th registered.

Uterine Cervical Dysplasia

410 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.

Browse Uterine Cervical Dysplasia studies →

Open to participants now

10 of the 109 studies in Uterine Cervical Dysplasia with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Uterine Cervical Dysplasia with a site in United States, or all of them as a file.
02

Study summary

This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.

03

Conditions studied

  • Cervical Intraepithelial Neoplasia
  • Uterine Neoplasms
  • Genital Neoplasms, Female
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent squamous or non-squamous cell carcinoma of the cervix with documented disease progression
  • Gynecologic Oncology Group (GOG) performance status 0-2
  • Patients must have received one prior systemic chemotherapy for persistent or recurrent disease
  • Patients with mild to moderate renal insufficiency should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs_ with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of pemetrexed.
  • All patients taking NSAIDs with longer half-lives, should interrupt dosing for at least 5 days before, the day of, and 2 days following pemetrexed administration.
  • Folic Acid (350-1000 ug) must be given daily beginning approximately 5-7 days prior to first does of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy.
  • Vitamin B12 (1000 ug) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy

Exclusion criteria

Exclusion Criteria:

  • Prior Pemetrexed
  • Patients who have received radiation to more than 25% of marrow bearing areas
  • Any evidence of other within last 5 years, with exception of non-melanoma skin cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    Drug: Pemetrexed

Interventions

  • Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.

06

What researchers measure

Primary outcomes

  1. Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

    Time frame: baseline to measured progressive disease (up to 5 years)

Secondary outcomes

  1. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

    Time frame: time of initial response until documented tumor progression (up to 5 years)

  2. Progression-Free Survival

    The period from study entry until disease progression, death or date of last contact.

    Time frame: baseline until documented tumor progression (up to 5 years)

  3. Overall Survival

    Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

    Time frame: baseline until death from any cause (up to 5 years)

07

Results

Posted Aug 24, 2009

Participant flow

Participant flow — Overall Study
MilestonePemetrexed
Started29
Completed27
Not completed2
Withdrew: Inevaluable (never treated)2

Outcome measures

PrimaryTumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

Time frame:
baseline to measured progressive disease (up to 5 years)
Reported as:
Number · participants
Tumor Response
participantsPemetrexed
Complete Response0
Partial Response4
Stable Disease16
Disease Progression7
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

Time frame:
time of initial response until documented tumor progression (up to 5 years)
Reported as:
Median · months
Duration of Response
monthsPemetrexed
Duration of Response4.4 (4.2 to 33.7)
SecondaryProgression-Free Survival

The period from study entry until disease progression, death or date of last contact.

Time frame:
baseline until documented tumor progression (up to 5 years)
Reported as:
Median · months
Progression-Free Survival
monthsPemetrexed
Progression-Free Survival3.1 (0.9 to 23.7)
SecondaryOverall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

Time frame:
baseline until death from any cause (up to 5 years)
Reported as:
Median · months
Overall Survival
monthsPemetrexed
Overall Survival7.4 (1.4 to 23.7)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed———
Most frequent serious events
Most frequent serious events
EventPemetrexed
Febrile neutropeniaBlood and lymphatic system disorders1/27
ThrombocytopeniaBlood and lymphatic system disorders1/27
Gastrointestinal haemorrhageGastrointestinal disorders1/27
PyelonephritisInfections and infestations1/27
Blood alkaline phosphatase increasedInvestigations1/27
Haemoglobin decreasedInvestigations1/27
White blood cell count decreasedInvestigations1/27
HypoalbuminaemiaMetabolism and nutrition disorders1/27
HypocalcaemiaMetabolism and nutrition disorders1/27
Female genital tract fistulaReproductive system and breast disorders1/27
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPemetrexed
AnemiaBlood and lymphatic system disorders23/27
ConstitutionalGeneral disorders21/27
MetabolicMetabolism and nutrition disorders20/27
LeukopeniaBlood and lymphatic system disorders19/27
NeutropeniaBlood and lymphatic system disorders17/27
GastrointestinalGastrointestinal disorders16/27
Nausea/vomitingGastrointestinal disorders13/27
PainGeneral disorders12/27
InfectionInfections and infestations12/27
Alkaline phosphataseInvestigations11/27

Baseline characteristics

Age, Customized
Age, Customized(participants)Pemetrexed
<40 years6
40-49 years9
50-59 years7
60-69 years4
>69 years1
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed
Female27
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed
White24
Black2
Asian1
Region of Enrollment
Region of Enrollment(participants)Pemetrexed
United States27
Cell Type
Cell Type(participants)Pemetrexed
Squamous19
Adenocarcinoma6
Clear cell1
Adenosquamous1
Gynecologic Oncology Group (GOG) Performance Status
Gynecologic Oncology Group (GOG) Performance Status(participants)Pemetrexed
0 - Fully active16
1 - Ambulatory, Restricted Strenuous Activity9
2 - Ambulatory, No Work Activities2
Prior Therapy
Prior Therapy(participants)Pemetrexed
Prior Chemotherapy27
No Prior Chemotherapy0
Prior Radiotherapy23
No Prior Radiotherapy4
Tumor Grade
Tumor Grade(participants)Pemetrexed
G1 - Well-Differentiated5
G2 - Moderately Differentiated15
G3 - Poorly Differentiated5
Unspecified2
08

Study locations

1 site
  • Gynecologic Oncology Group 215-854-0770
    Philadelphia, Pennsylvania, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Feb 2005
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
Aug 24, 2009
Last update
Nov 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00190983
First posted
Sep 19, 2005
Start date
Feb 2005
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Aug 24, 2009
Last update
Nov 20, 2009

Study contacts

David Miller, MD
study chair · Gynecologic Oncology Group
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion